Several top U.S. business schools are skipping popular M.B.A. rankings this year, upending an annual rite for programs and prospective students.

Harvard Business School, the University of Pennsylvania’s Wharton School, Columbia Business School and the Stanford Graduate School of Business, among others, opted to skip the most recent rankings by the Economist and the Financial Times. Several schools said Covid-19 made it difficult to gather the data they must submit to be ranked.

More than bragging rights hang in the balance—though there are plenty of those, too. Schools say a good showing in rankings can draw interest from prospective students, stoking application volumes, as well as plaudits or pans from alumni who continue to track their alma mater long after leaving campus.

Overall, 62% of programs plan to participate in some rankings, while 10% don’t plan to cooperate for any lists this year, according to a survey of business-school admissions officials by Kaplan, the education subsidiary of the Graham Holdings Co.

Bloomberg Businessweek suspended its 2020 ranking, the only major list to do so. Dozens of notable schools were missing from the Economist’s list published last month. Nine schools that normally take part in the FT’s list chose not to participate, a spokeswoman said.

This post first appeared on wsj.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Fear of more quakes haunts Turkish rescuers trying to save survivors from the wreckage

Gaziantep, an ancient Turkish city badly damaged by the massive 7.8 magnitude earthquake that…

Americans for Prosperity super PAC launches Senate ads in two key states

Americans for Prosperity Action, the super PAC arm of the conservative political…

Arm & Hammer Maker Executive Is Docked $200,000 Over Deleted Texts

Share Listen (1 min) This post first appeared on wsj.com

Universal flu vaccine based on mRNA tech to be tested by National Institutes of Health

Patients are now enrolling in an early-stage clinical trial to test a universal…